ASCO 2019: Supportive Care and Developments in Gynecological Cancer

07/15/19 • 44 min

In this episode of The Onco’Zine Brief, recorded during the annual meeting of the American Society of Clinical Oncology, ASCO, being held May 31 – June 4, 2019, Peter Hofland talks with Lee Schwartzberg MD, FACP, is a Medical Oncologist and Hematologist at West Cancer Center, Germantown, TN, and Dr. Shannon Westin, MD, MPH., FACOG, Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies.
Today in The OncoZine Brief Hofland an hus guests discuss two different aspects of the treatment of cancer: palliative and supportive care and the treatment of Gynecological cancers.
Hofland's interview with Dr. Lee Schwartzberg confirmed the importance of Palliative and supportive care in the treatment of patients with cancer. In essence, Palliative care is focused on improving the quality of life for people living with a serious illness like cancer. People with cancer may receive palliative care at any time from the point of diagnosis, throughout treatment, and beyond. This kind of care helps patients and caregivers manage the symptoms of cancer and side effects of treatment.
In the second part of the program, Hofland and Dr. Shannon Westinwe spoke about the progress made in the treatment of Gynecological cancers.
While all women are at risk for gynecologic cancers, and this risk increases with age, when gynecologic cancers are found early, treatment is most effective. But, the diagnosis of gynecological cancers can be difficult. In America, every six minutes a woman is diagnosed with a gynecologic cancer. And, according to the American Cancer Society, this year alone an estimated be 92,000 women will be diagnosed with a gynecological cancer in the United States. Sadly, this will also result in a predicted 28,000 women killed by various forms of this group of cancers.
Some of these gynecologic cancers have been called “silent killers” because women are often unaware of the signs and symptoms associated with these cancers and do not catch them until it is too late.
For more information, go to Onco'Zine at www.oncozine.com
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

Previous Episode

ASCO 2019: The Courage and Expertese to Outsmart Cancer

In this episode of The Onco’Zine Brief Peter Hofland report from the annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st – June 4th, 2019.
The American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. During the annual meeting Peter Hofland spoke with:
• Anna Protopapas, the president and Chief Executive Office of Mersana Therapeutics, a clinical stage biotech company developing antibody-drug conjugates – a very specific kind of targeted anti-cancer drug;
• Eliran Malki, the Chief executive officer of BELONG.life, the world’s largest social network for cancer patients and caregivers designed to gain a better understanding of the cancer patient journey, with the goal of optimizing treatment and outcomes;
• Dr. Rod Humerickhouse, asset strategy leader oncology at AbbVie, a highly focused research-driven biopharmaceutical company. As a major developer of anticancer drugs, AbbVie’s oncology scientists understand that outsmarting cancer takes a potent combination of courage, scientific expertise and strategy.
For more information, go to Onco'Zine at www.oncozine.com
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

Next Episode

ASCO 2019: Form Biomarker Discovery to Photo-Immunotherapy

In this episode of the Onco’Zine Brief Peter Hofland reports from the 2019 annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st – June 4th, 2019.
Hofland talks with:
- Dr. Hartmut Juhl, the Chief Executive Officer of Indivumed, a physician-led, integrated global oncology company. The company offers specialized products and services designed to support the discovery of biomarkers, drug development, clinical trials, and individualized treatment for patients with cancer, and
- Dr. Jeannie Hou, Vice President Clinical Development at Rakuten Medical, a company developing precision-targeted medicines through the development of a novel, proprietary photo-immunotherapy platform.
For more information, please visit Onco'Zine at www.oncozine.com
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.